These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15254195)

  • 1. APOBEC3G targets specific virus species.
    Kobayashi M; Takaori-Kondo A; Shindo K; Abudu A; Fukunaga K; Uchiyama T
    J Virol; 2004 Aug; 78(15):8238-44. PubMed ID: 15254195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APOBEC3G targets human T-cell leukemia virus type 1.
    Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
    Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
    Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.
    Shindo K; Takaori-Kondo A; Kobayashi M; Abudu A; Fukunaga K; Uchiyama T
    J Biol Chem; 2003 Nov; 278(45):44412-6. PubMed ID: 12970355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Mariani R; Chen D; Schröfelbauer B; Navarro F; König R; Bollman B; Münk C; Nymark-McMahon H; Landau NR
    Cell; 2003 Jul; 114(1):21-31. PubMed ID: 12859895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protecting APOBEC3G: a potential new target for HIV drug discovery.
    Stopak K; Greene WC
    Curr Opin Investig Drugs; 2005 Feb; 6(2):141-7. PubMed ID: 15751736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
    Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
    J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human APOBEC3G incorporation into murine leukemia virus particles.
    Kremer M; Bittner A; Schnierle BS
    Virology; 2005 Jun; 337(1):175-82. PubMed ID: 15914230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
    Xu H; Chertova E; Chen J; Ott DE; Roser JD; Hu WS; Pathak VK
    Virology; 2007 Apr; 360(2):247-56. PubMed ID: 17126871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA deamination mediates innate immunity to retroviral infection.
    Harris RS; Bishop KN; Sheehy AM; Craig HM; Petersen-Mahrt SK; Watt IN; Neuberger MS; Malim MH
    Cell; 2003 Jun; 113(6):803-9. PubMed ID: 12809610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.
    Russell RA; Wiegand HL; Moore MD; Schäfer A; McClure MO; Cullen BR
    J Virol; 2005 Jul; 79(14):8724-31. PubMed ID: 15994766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.
    Izumi T; Shirakawa K; Takaori-Kondo A
    Mini Rev Med Chem; 2008 Mar; 8(3):231-8. PubMed ID: 18336343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC-mediated interference with hepadnavirus production.
    Rösler C; Köck J; Kann M; Malim MH; Blum HE; Baumert TF; von Weizsäcker F
    Hepatology; 2005 Aug; 42(2):301-9. PubMed ID: 16025511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
    Luo K; Liu B; Xiao Z; Yu Y; Yu X; Gorelick R; Yu XF
    J Virol; 2004 Nov; 78(21):11841-52. PubMed ID: 15479826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Liddament MT; Brown WL; Schumacher AJ; Harris RS
    Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOBEC family proteins: novel antiviral innate immunity.
    Takaori-Kondo A
    Int J Hematol; 2006 Apr; 83(3):213-6. PubMed ID: 16720550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
    Kaiser SM; Emerman M
    J Virol; 2006 Jan; 80(2):875-82. PubMed ID: 16378989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
    Dutko JA; Schäfer A; Kenny AE; Cullen BR; Curcio MJ
    Curr Biol; 2005 Apr; 15(7):661-6. PubMed ID: 15823539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.